$PCRX News

Pacira Biosciences Inc (NASDAQ:PCRX) Emerges as a Deep Value Opportunity with Strong Financial Health

Pacira BioSciences Announces Findings From Real-World Study Evaluating Outcomes Associated With Use Of EXPAREL Following Outpatient Total Shoulder Arthroplasty In Medicare Advantage Patients

Pacira BioSciences: Exparel Still Supports My Original Bull Case

Pacira BioSciences' (NASDAQ:PCRX) Performance Is Even Better Than Its Earnings Suggest

DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates

Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Mails Letter to Stockholders

PACIRA BIOSCIENCES INC (NASDAQ:PCRX): A Value Stock Candidate with Margin of Safety

Assessing Pacira BioSciences (PCRX) Valuation After Earnings Update And New EXPAREL Real World Data

Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $24

Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release

Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $32

Pacira BioSciences Inc (PCRX) Q1 2026 Earnings Call Highlights: Strong Product Growth Amidst ...

Pacira BioSciences Q1 Earnings Call Highlights

Pacira BioSciences, Inc. Q1 2026 Earnings Call Summary

Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript

Pacira (PCRX) Q1 2026 Earnings Call Transcript

Pacira (PCRX) Q1 Earnings Miss Estimates